Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ImmunityBio
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Phase II/III studies are underway for Mesoblast’s remestemcel-L and Athersys’ Multistem, followed by a pack of earlier-stage stem cell candidates from Pluristem, Hope Bioscience and Celltex – with an interactive chart of the COVID-19 cell therapy pipeline.
- Other Names / Subsidiaries